RecruitingNCT05745389
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Sponsor
CorEvitas
Enrollment
5,000 participants
Start Date
Oct 25, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- A subject must meet all the following criteria to participate in the registry:
- Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner.
- Is at least 18 years of age or older.
- Is willing to provide Personal Information.
- Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment.
Exclusion Criteria3
- Any of the following would exclude the subject from participating in the registry:
- Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:
- Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05745389
Related Trials
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
NCT072265311 location
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT0753300629 locations
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240268 locations
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
NCT061048392 locations
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT0653110958 locations